Michael Barbella, Managing Editor05.09.23
Rhythmlink International LLC has forged a new investment partnership with Graham Partners, a Pennsylvania-based private equity firm that specializes in industrial technology and advanced manufacturing businesses.
Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth continues, according to company bigwigs. The investment was completed earlier this year.
“We’re excited about this next phase of Rhythmlink,” Rhythmlink Co-Founder/CEO Shawn Regan said. “Graham is an excellent partner for us because of their experience in medical technology and healthcare, and we see this as a growth opportunity for us to continue to innovate beyond our current capabilities. I’m extremely proud of how far we’ve come, and this is a chance for Rhythmlink to expand our business without sacrificing what matters to us—improving patient care in our field of neurodiagnostics.”
This new relationship with Graham follows Rhythmlink’s successful partnership with New Heritage Capital, a Boston-based private equity firm that invested in Rhythmlink in 2019. Under the partnership with New Heritage, Rhythmlink grew rapidly, acquired Chalgren Enterprises and expanded its existing product line to include EMG and NCV diagnostic consumable devices.
“Our partnership with New Heritage was extremely beneficial,” Rhythmlink Chief Operating Officr/Chief Financial Officer Joe Straczek stated. “With their support, both financially and strategically, we were able to realize significant growth, particularly with the acquisition of Chalgren. We are immensely grateful for their partnership and guidance over the last four years.”
Rhythmlink sells consumable neurodiagnostic devices for critical care, electroencephalography, intraoperative neuromonitoring, the emergency room and ICU, and long-term epilepsy monitoring.
Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth continues, according to company bigwigs. The investment was completed earlier this year.
“We’re excited about this next phase of Rhythmlink,” Rhythmlink Co-Founder/CEO Shawn Regan said. “Graham is an excellent partner for us because of their experience in medical technology and healthcare, and we see this as a growth opportunity for us to continue to innovate beyond our current capabilities. I’m extremely proud of how far we’ve come, and this is a chance for Rhythmlink to expand our business without sacrificing what matters to us—improving patient care in our field of neurodiagnostics.”
This new relationship with Graham follows Rhythmlink’s successful partnership with New Heritage Capital, a Boston-based private equity firm that invested in Rhythmlink in 2019. Under the partnership with New Heritage, Rhythmlink grew rapidly, acquired Chalgren Enterprises and expanded its existing product line to include EMG and NCV diagnostic consumable devices.
“Our partnership with New Heritage was extremely beneficial,” Rhythmlink Chief Operating Officr/Chief Financial Officer Joe Straczek stated. “With their support, both financially and strategically, we were able to realize significant growth, particularly with the acquisition of Chalgren. We are immensely grateful for their partnership and guidance over the last four years.”
Rhythmlink sells consumable neurodiagnostic devices for critical care, electroencephalography, intraoperative neuromonitoring, the emergency room and ICU, and long-term epilepsy monitoring.